25th Feb 2008 07:00
Henderson Morley PLC25 February 2008 25 FEBRUARY 2008 HENDERSON MORLEY PLC (AIM) Business: Drug Discovery Company POSITIVE PREPS STUDY OUTCOME The Board of Henderson Morley plc, the AIM listed vaccine and anti-viral drugdevelopment company, is pleased to announce the completion of studies regardingits PREPS and L-particles vaccine platform. The studies were undertaken by a US-based contract research organisation, andexamined safety, antigenicity and immunogenicity of PREPS and L-particles inlaboratory models. HIGHLIGHTS • PREPS and L-particles demonstrated to be stable, safe, and well tolerated. • These positive results will now lead to further studies. • These technologies are being developed to target a number of important diseases. PREPS and L-particles were demonstrated to be stable, safe, and well tolerated.The studies also demonstrated that a potent and dose related immune response wasgenerated to the target antigen. These positive results will now lead to furtherstudies examining engineered PREPS and L-particles targeted at either cancer orother model antigens. These studies will aide the further development of PREPS and L-particles ascancer immunotherapeutic candidates. The studies will also aide withidentification and selection of lead candidate vaccines. These technologies are being developed to target a number of important diseasesincluding virus infections in humans such as Cytomegalovirus, Epstein Barr virusand herpes simplex virus, and as a cancer immunotherapy for a wide range ofdifferent forms of human and animal cancers. Executive Chairman Andrew Knight said: "We are delighted with the initialpositive outcome of these studies. We are working on an important vaccineprogramme and look forward to further developing our technologies to target awide range of diseases. " ---ENDS--- Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600Andrew Knight, Chairman BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7562 3350Maxine BarnesNick Rome BREWIN DOLPHIN LTD Tel: 0113 241 0126Neil Baldwin Notes for editors Antigenicity and immunogenicity- ability of vaccine to develop an immuneresponse PREPS and L-particles This vaccine platform has a wide range of potential applications including, butnot limited to: Infectious disease- HSV, CMV, EBV, Cancer- immunotherapeutic against a wide range of antigens DNA vaccines- as a biological adjuvant This vaccine platform has a number of distinct advantages over existingtechnologies: Virus like particles that contain full complement of virus proteins Non replicating and contain no DNA Wide range of proteins may be expressed This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
HML.L